BRPI0615898B8 - composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável - Google Patents

composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável

Info

Publication number
BRPI0615898B8
BRPI0615898B8 BRPI0615898A BRPI0615898A BRPI0615898B8 BR PI0615898 B8 BRPI0615898 B8 BR PI0615898B8 BR PI0615898 A BRPI0615898 A BR PI0615898A BR PI0615898 A BRPI0615898 A BR PI0615898A BR PI0615898 B8 BRPI0615898 B8 BR PI0615898B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
solvate
hydrate
pharmaceutical composition
Prior art date
Application number
BRPI0615898A
Other languages
English (en)
Inventor
Hamilton Lithgow Bruce
Tokunbo Adesuyi Charles
Holman Lovelace
Lambert Olivier
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0615898(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0615898A2 publication Critical patent/BRPI0615898A2/pt
Publication of BRPI0615898B1 publication Critical patent/BRPI0615898B1/pt
Publication of BRPI0615898B8 publication Critical patent/BRPI0615898B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável. a invenção refere-se às composições farmacêuticas estáveis compreendendo o composto de fórmula abaixo, ou sais, solvatos, hidratos ou formas morfológicas do mesmo farmaceuticamente aceitáveis.
BRPI0615898A 2005-09-12 2006-09-11 composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável BRPI0615898B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP/2005/009775 2005-09-12
EP2005009775 2005-09-12
PCT/IB2006/053210 WO2007031933A2 (en) 2005-09-12 2006-09-11 Stable pharmaceutical composition comprising a pyrimidine-sulfamide

Publications (3)

Publication Number Publication Date
BRPI0615898A2 BRPI0615898A2 (pt) 2011-05-31
BRPI0615898B1 BRPI0615898B1 (pt) 2020-02-18
BRPI0615898B8 true BRPI0615898B8 (pt) 2021-05-25

Family

ID=37865339

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615898A BRPI0615898B8 (pt) 2005-09-12 2006-09-11 composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável

Country Status (23)

Country Link
US (6) US20080233188A1 (pt)
EP (2) EP1928409B1 (pt)
JP (2) JP4955685B2 (pt)
KR (1) KR101313395B1 (pt)
CN (1) CN101262847B (pt)
AU (1) AU2006290309B2 (pt)
BR (1) BRPI0615898B8 (pt)
CA (1) CA2621273C (pt)
CY (1) CY1113395T1 (pt)
DK (1) DK1928409T3 (pt)
ES (1) ES2393117T3 (pt)
HR (1) HRP20120957T1 (pt)
IL (1) IL190072A (pt)
MY (1) MY151003A (pt)
NO (1) NO341325B1 (pt)
NZ (1) NZ567188A (pt)
PL (1) PL1928409T3 (pt)
PT (1) PT1928409E (pt)
RU (1) RU2424805C2 (pt)
SI (1) SI1928409T1 (pt)
TW (1) TWI323661B (pt)
WO (1) WO2007031933A2 (pt)
ZA (1) ZA200802947B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8541433B2 (en) * 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
ES2543280T3 (es) * 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
IT1403248B1 (it) * 2010-11-12 2013-10-17 Scharper Therapeutics Srl Composizione per il trattamento di disfunzioni degli apparati fonatorio ed olfattorio
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme
DE14721256T1 (de) * 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
US20170158645A1 (en) * 2014-07-15 2017-06-08 Olon S.P.A. Amorphous form and new crystalline forms of macitentan
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
CN105388244B (zh) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 一种马西替坦有关物质的高效液相色谱分析方法
WO2018153925A1 (en) 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
CA3123990A1 (en) 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020277546B2 (en) 2019-05-22 2025-07-03 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of pyrimidine sulfonamide compound and preparation method therefor
MX2022000267A (es) * 2019-07-05 2022-02-03 Tecnimede Sociedade Tecnico Medicinal Sa Composiciones comprimidas de macitentan, metodos y usos de las mismas.
CN114728002A (zh) 2019-11-29 2022-07-08 埃科特莱茵药品有限公司 治疗肺动脉高血压的方法
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
TW202317119A (zh) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 用於口服投予之分散錠
EP4392024A1 (en) 2021-08-25 2024-07-03 Basf Se Direct tableting auxiliary composition
TR2021013983A1 (tr) * 2021-09-07 2023-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Masi̇tentan i̇çeren bi̇r kapsül formülasyonu
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
WO1997022595A1 (en) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
JPH103525A (ja) 1996-06-14 1998-01-06 Dainippon Printing Co Ltd Ｉｃカード、命令コード格納方法及び命令コード実行方法
AR017426A1 (es) 1997-12-08 2001-09-05 Smithkline Beecham Corp Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20040062803A1 (en) * 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
HUP0203935A3 (en) * 1999-12-31 2006-02-28 Encysive Pharmaceuticals Inc H Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
WO2002043704A1 (fr) 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition a solubilite ou absorbabilite orale amelioree
IL156315A0 (en) 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
HU229403B1 (en) * 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
JP3930290B2 (ja) 2001-09-12 2007-06-13 富士フイルム株式会社 熱現像感光材料及びそれを用いた熱現像方法
KR20030041577A (ko) 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
WO2003057166A2 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
KR100698982B1 (ko) 2002-02-11 2007-03-26 화이자 인코포레이티드 Ｐｄｅ4 억제제로서 유용한 니코틴아미드 유도체
KR20100090726A (ko) * 2002-02-26 2010-08-16 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
HRP20050675A2 (en) 2003-02-25 2005-10-31 Eli Lilly And Company Crystalline non-solavated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
EP1697382A4 (en) 2003-12-10 2008-11-05 Activbiotics Inc ANALOGUES OF RIFAMYCIN AND USES THEREOF
US7094081B1 (en) * 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8541433B2 (en) 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme

Also Published As

Publication number Publication date
AU2006290309B2 (en) 2012-04-05
EP2292209A2 (en) 2011-03-09
HRP20120957T1 (hr) 2012-12-31
JP5054061B2 (ja) 2012-10-24
PT1928409E (pt) 2012-11-27
CN101262847B (zh) 2010-11-24
CA2621273A1 (en) 2007-03-22
TWI323661B (en) 2010-04-21
EP2292209A3 (en) 2011-05-04
IL190072A (en) 2013-08-29
US8367685B2 (en) 2013-02-05
CA2621273C (en) 2014-07-29
TW200803860A (en) 2008-01-16
US10946015B2 (en) 2021-03-16
HK1121950A1 (en) 2009-05-08
US20160136163A1 (en) 2016-05-19
EP1928409B1 (en) 2012-09-12
RU2008113869A (ru) 2009-10-20
SI1928409T1 (sl) 2012-12-31
US20180263980A1 (en) 2018-09-20
NO341325B1 (no) 2017-10-16
MY151003A (en) 2014-03-31
WO2007031933A2 (en) 2007-03-22
JP2009235073A (ja) 2009-10-15
CN101262847A (zh) 2008-09-10
US9265762B2 (en) 2016-02-23
PL1928409T3 (pl) 2013-02-28
ZA200802947B (en) 2009-12-30
US20100004274A1 (en) 2010-01-07
US10117870B2 (en) 2018-11-06
CY1113395T1 (el) 2016-06-22
US11648249B2 (en) 2023-05-16
NZ567188A (en) 2011-04-29
WO2007031933A3 (en) 2007-10-18
BRPI0615898B1 (pt) 2020-02-18
US20210186966A1 (en) 2021-06-24
ES2393117T3 (es) 2012-12-18
DK1928409T3 (da) 2012-11-05
US20130190336A1 (en) 2013-07-25
KR20080055897A (ko) 2008-06-19
EP1928409A2 (en) 2008-06-11
IL190072A0 (en) 2008-08-07
NO20081724L (no) 2008-04-09
JP4955685B2 (ja) 2012-06-20
KR101313395B1 (ko) 2013-10-02
JP2009519893A (ja) 2009-05-21
BRPI0615898A2 (pt) 2011-05-31
RU2424805C2 (ru) 2011-07-27
AU2006290309A1 (en) 2007-03-22
US20080233188A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
BRPI0615898B8 (pt) composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
EA201070786A1 (ru) Бензофуропиримидиноны
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
TW200716614A (en) Substituted arylpyrazoles
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
EA200970156A1 (ru) Пиридизиноновые производные
HN2012001162A (es) Triazolopiridinas
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
BRPI0516609A (pt) composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto
MY143698A (en) Substituted morpholine and thiomorpholine derivatives.
MX2009006284A (es) Arilpirazoles sustituidos.
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
BRPI0917661B8 (pt) produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TN2010000038A1 (en) Organic compounds
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
SG158091A1 (en) Imidazoazepinone compounds
UA130690C2 (uk) Інгібітори о-глікопротеїн-2-ацетамідо-2-деокси-3-d-глюкопіранозидази
UY27980A1 (es) Indoles 2,7-sustituidos
TW200736227A (en) New compounds III
TW200745122A (en) New compounds I
ECSP088374A (es) Formulacion de aerosol para inhalacion
CR20110082A (es) Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF